10 28 2004 12 36 02 pm 240827 curry sl page 01 q3 results presentation to analysts & investors 28th october summary absorbed significant generic erosion paxil wellbutrin excluding pharma sales grew 8 in on track deliver full year guidance improved eps growth q4 pipeline momentum rotarix rotavirus lapatinib solid tumours excellent efficacy safety profile eu int market opportunity 0 5bn filing 2005 first dual acting oral erbb 1 b 2 inhibitor demonstrated response herceptin failures us breast cancer key filings requip cr coreg avandamet xr once daily formulations of drivers american academy neurology trexima sumatriptan naproxen is being developed collaboration with pozen inc migraine targeting superior imitrex phase ii data be presented at aan early
